© 2024 Connecticut Public

FCC Public Inspection Files:
WPKT · WRLI-FM · WEDW-FM · Public Files Contact
Play Live Radio
Next Up:
0:00 0:00
Available On Air Stations
Cancer Answers is hosted by Dr. Anees Chagpar, Associate Professor of Surgical Oncology and Director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven Hospital, and Dr. Francine Foss, Professor of Medical Oncology. The show features a guest cancer specialist who will share the most recent advances in cancer therapy and respond to listeners questions. Myths, facts and advances in cancer diagnosis and treatment are discussed, with a different focus eachweek. Nationally acclaimed specialists in various types of cancer research, diagnosis, and treatment discuss common misconceptions about the disease and respond to questions from the community.Listeners can submit questions to be answered on the program at canceranswers@yale.edu or by leaving a message at (888) 234-4YCC. As a resource, archived programs from 2006 through the present are available in both audio and written versions on the Yale Cancer Center website.

Alzheimer's Treatment Based on Connecticut Research Goes Into Clinical Trials

Harriet Jones
A prototype of the device patented by Eric Knight, designed to deliver radio waves to the brain.

A device to treat Alzheimer’s Disease using radio waves has gone into clinical trials in Arizona. The trial is partially backed by science carried out in Connecticut. 

Farmington-based inventor Eric Knight patented a device which delivers radio waves to the brains of Alzheimers sufferers. After the patent was issued he teamed up with the Alzheimer’s specialist, Dr. Gary Arendash, who carried out the basic research into the approach.

Now the two have launched a clinical trialinvolving a dozen patients at the Banner Institute in Phoenix.

"We're really proud to be working with one of the top facilities in America," said Knight. "This is exciting beyond words."

Patients in the trial will wear the device twice a day, an hour at a time over the two month period. They'll be given baseline cognitive tests before and after the trial.

A study in mice showed that the effects of dementia in Alzheimer's could be halted and even reversed with the technique.

Knight said the research should be able to prove basic efficacy and safety quickly.

"We’re hopeful that by springtime we will have a sense for how this is all working with the patients," he said. "Which is blazingly fast compared to traditional pharmaceutical medications in development and testing. So this is a kind of light speed, warp speed research that’s happening right now."

If the device is proved effective, it will go into more rounds of trials with a larger cohort of patients, perhaps at multiple sites.

The research is partially funded by cash from angel investors based in Connecticut.

Harriet Jones is Managing Editor for Connecticut Public Radio, overseeing the coverage of daily stories from our busy newsroom.

Stand up for civility

This news story is funded in large part by Connecticut Public’s Members — listeners, viewers, and readers like you who value fact-based journalism and trustworthy information.

We hope their support inspires you to donate so that we can continue telling stories that inform, educate, and inspire you and your neighbors. As a community-supported public media service, Connecticut Public has relied on donor support for more than 50 years.

Your donation today will allow us to continue this work on your behalf. Give today at any amount and join the 50,000 members who are building a better—and more civil—Connecticut to live, work, and play.

Related Content